by Portfolio Grader | March 13, 2013 2:00 pm
This week, five Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Ariad Pharmaceuticals (NASDAQ:ARIA) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The stock price has risen 10.3% over the past month, better than the 1.6% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
The rating of Neurocrine Biosciences (NASDAQ:NBIX) moves up this week, rising from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) shows solid improvement this week. The company’s rating rises from a C to a B. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Investors have pushed the stock price up 17.6% over the past month. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics (NASDAQ:CLDX) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. Wall Street has pushed the stock higher by 53.2% over the past month. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Insmed Inc. (NASDAQ:INSM) improves from a C to a B rating this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 5.8% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/03/5-biotechnology-stocks-to-buy-now-aria-nbix-arry/
Short URL: http://invstplc.com/1nvSsAN